Apixaban following discharge in hospitalised adults with COVID-19: Preliminary results from a multicentre, open-label, randomised controlled platform clinical trial

Mark R Toshner, Carrol Gamble, J Kenneth Baillie, Ashley Best, Emma Bedson, Judy Bradley, Melanie Calvert, Elin Haf Davies, Annemarie B Docherty, Efstathia Gkioni, Dyfrig A Hughes, Thomas Jaki, R Gisli Jenkins, Ashley Jones, Martin J Landray, Jonathan Mant, Daniel F McAuley, Peter JM Openshaw, Duncan Richards, Paul Wicks, HEAL-COVID Collaboration, Charlotte Summers
doi: https://doi.org/10.1101/2022.12.07.22283175

Article usage

Article usage: December 2022 to December 2024

AbstractFullPdf
Dec 2022181124211
Jan 20232575058
Feb 2023154834
Mar 2023122429
Apr 2023126215
May 202310016
Jun 20237558
Jul 20236213
Aug 2023811018
Sep 2023100613
Oct 2023871320
Nov 202366610
Dec 202310505
Jan 2024140410
Feb 202458126
Mar 2024139514
Apr 20249938
May 202480310
Jun 202460823
Jul 202444613
Aug 20249667
Sep 20246226
Oct 20246139
Nov 202455510
Dec 20242135
Back to top
Posted December 07, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Apixaban following discharge in hospitalised adults with COVID-19: Preliminary results from a multicentre, open-label, randomised controlled platform clinical trial
Mark R Toshner, Carrol Gamble, J Kenneth Baillie, Ashley Best, Emma Bedson, Judy Bradley, Melanie Calvert, Elin Haf Davies, Annemarie B Docherty, Efstathia Gkioni, Dyfrig A Hughes, Thomas Jaki, R Gisli Jenkins, Ashley Jones, Martin J Landray, Jonathan Mant, Daniel F McAuley, Peter JM Openshaw, Duncan Richards, Paul Wicks, HEAL-COVID Collaboration, Charlotte Summers
medRxiv 2022.12.07.22283175; doi: https://doi.org/10.1101/2022.12.07.22283175
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area